Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted therapies for renal cell carcinoma.
Posadas EM, Limvorasak S, Figlin RA. Posadas EM, et al. Nat Rev Nephrol. 2017 Aug;13(8):496-511. doi: 10.1038/nrneph.2017.82. Epub 2017 Jul 10. Nat Rev Nephrol. 2017. PMID: 28691713 Review.
Kinase inhibitors in prostate cancer.
Limvorasak S, Posadas EM. Limvorasak S, et al. Among authors: posadas em. Anticancer Agents Med Chem. 2009 Dec;9(10):1089-104. doi: 10.2174/187152009789735080. Anticancer Agents Med Chem. 2009. PMID: 19925393 Review.
Pazopanib: therapeutic developments.
Limvorasak S, Posadas EM. Limvorasak S, et al. Among authors: posadas em. Expert Opin Pharmacother. 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493. Expert Opin Pharmacother. 2009. PMID: 19954277 Review.
Understanding the role of MET kinase in cancer therapy.
Posadas EM, Figlin RA. Posadas EM, et al. J Clin Oncol. 2013 Jan 10;31(2):169-70. doi: 10.1200/JCO.2012.46.7738. Epub 2012 Dec 3. J Clin Oncol. 2013. PMID: 23213104 No abstract available.
Targeting angiogenesis in renal cell carcinoma.
Posadas EM, Limvorasak S, Sharma S, Figlin RA. Posadas EM, et al. Expert Opin Pharmacother. 2013 Nov;14(16):2221-36. doi: 10.1517/14656566.2013.832202. Epub 2013 Aug 28. Expert Opin Pharmacother. 2013. PMID: 23984807 Review.
Third-Line Treatment Options for Kidney Cancer.
Posadas EM, Limvorasak S, Figlin RA. Posadas EM, et al. Oncology (Williston Park). 2016 Sep 15;30(9):813-5. Oncology (Williston Park). 2016. PMID: 27633411 Free article. No abstract available.
139 results